BOSTON, April 25, 2025--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug ...

Nimbus Therapeutics Announces Initiation of First-in-Human Clinical Trial with NDI-219216, Novel WRN Inhibitor for MSI-H Tumors Provided by Business Wire Apr 25, 2025, 5:00:00 PM ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines through its powerful computational drug discovery engine ...

Nimbus' pipeline includes NDI-219216, a Werner syndrome helicase (WRN) inhibitor in development for microsatellite instability high (MSI-H) tumors, as well as a diverse portfolio of preclinical ...

BOSTON, March 07, 2025--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful ...

BOSTON, February 25, 2025--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful ...

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics has announced a significant development in its quest to advance paxalisib, a promising treatment for newly diagnosed ...

Nimbus Therapeutics raises $210 million in one of the larger fund-raising rounds this year The Boston-based biotech will work on new “small molecule” drugs to combat cancer and other ailments ...

Nimbus Therapeutics said Wednesday it has raised $210 million in venture capital to advance its pipeline of drugs to combat other disorders, including cancer.